跳至主要内容
临床试验/NCT00773539
NCT00773539Unknown4 期

Safety and Efficacy of Transvenous Pulmonary Isolation for the Treatment of Atrial Fibrillation: A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy

Herz-Zentrums Bad Krozingen2 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2008年7月1日最近更新:
适应症

试验速览

阶段
4 期
发起方
入组人数
78
试验地点
2
主要终点
Changes of platelet function (number of patients with an increase of more than 100% in platelets positive for either P-selectin or activated GP IIb/IIIa)

研究概览

简要总结

Transvenous pulmonary vein (PV) isolation using radiofrequency energy is an effective treatment for atrial fibrillation (1-4). However, rare but potentially life threatening complications such as thromboembolism (5), PV stenosis (5-10), left atrium-oesophageal fistula (11) and inflammatory syndromes (12) have been described. In preliminary studies an alternate approach using cryoenergy induces less endothelial disruption/ thrombus formation (13), preserves the extra cellular matrix and creates lesions with well-delineated border zones (14). Therefore, cryoenergy seems to be the ideal form of energy to safely perform PV isolation.

We therefore hypothesise that in the setting of PV isolation for the treatment of atrial fibrillation (AF) cryoenergy is less traumatic and therefore reduces systemic inflammatory responses compared to radiofrequency energy.

78 patients presenting with symptomatic intermittent or persistent AF will be randomised to PV isolation with either radiofrequency (26 patients open irrigated tip, 26 patients closed irrigated tip) or cryoenergy (26 patients with cryoballoon). Systemic markers of cell damage and inflammatory response (t-troponin, CK, CK-MB, vWF, PAI-1, micro particles, platelet activation/overall function, CRP, IL-6, IL-8, IL-10, TNF alpha, procalcitonin) will be monitored before, during and 48h after the procedure. Further endpoints include time to PV-isolation and procedure related complications. Six month clinical follow-up will focus on freedom from AF and cardiovascular events.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age between 18 and 75 years
  • Symptomatic drug refractory (more than 2 antiarrhythmic drugs) paroxysmal or persistent AF
  • Documentation of AF on 12 lead ECG and/ or Holter
  • Left atrium of less than 55 mm
  • Informed consent signed by the patient

排除标准

  • Previous Ablation or operation for AF
  • Contra-indication for heart catheterisation
  • Cardioversion for AF during the 2 weeks before the procedure

结局指标

主要结局

Changes of platelet function (number of patients with an increase of more than 100% in platelets positive for either P-selectin or activated GP IIb/IIIa)

时间窗: before, at the end of intervention, 6, 24 and 48 hours later.

次要结局

  • Parameters of inflammation and tissue damage, the time to achieve PV-Isolation, freedom from AF.(before, during and 6 months after procedure)

研究者

发起方
Herz-Zentrums Bad Krozingen
申办方类型
Other

研究点 (2)

Loading locations...

相似试验